<html>
        <head>
            <link rel="stylesheet" type="text/css" href="layout.css" />
        </head>
        <style> 
            .right { 
                margin-left: 160px;
            } 
        </style>
        
        <div class="sidenav">
            <a href="#">About</a>
            <a href="index_gpt.html">Index</a>
        </div>
    <div class="header"><h3>RACE II</h3></div><p><span class="main">"Lenient vs Strict Rate Control in Patients with Atrial Fibrillation". The New England Journal of Medicine. 2010. 362:1363-1373.  </span></p><p><span class="contents">
                                        Links to original sources:
                                        <a href=https://www.wikijournalclub.org//wiki/RACE_II>Wiki Journal Post</a>
                                        <a href=http://www.nejm.org/doi/full/10.1056/NEJMoa1001337>Full Journal Article</a>
                                        </span></p><p><span class="main">Contents
1 Clinical Question
2 Bottom Line
3 Major Points
4 Guidelines
5 Design
6 Population
6.1 Inclusion Criteria
6.2 Exclusion Criteria
6.3 Baseline Characteristics
7 Interventions
8 Outcomes
8.1 Primary Outcome
8.2 Secondary Outcomes
9 Criticisms
10 Funding
11 Further Reading
 </span></p><h2><span class="labels">Clinical Question</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">In patients with permanent atrial fibrillation, is lenient rate control inferior to strict rate control for preventing cardiovascular morbidity and mortality?
 </span></p><h2><span class="labels">Bottom Line</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">In patients with permanent atrial fibrillation, lenient rate control was not inferior to strict rate control for the prevention of cardiovascular morbidity and mortality and was easier to achieve.
 </span></p><h2><span class="labels">Major Points</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">The Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison between Lenient vs Strict Rate Control II (RACE II) study challenged the longstanding practice of strict rate control in atrial fibrillation. This study found that a lenient rate-control strategy (resting heart rate <110 beats per minute) was noninferior to a strict rate-control strategy (resting heart rate <80 beats per minute and heart rate during moderate exercise <110 beats per minute) regarding the prevention of cardiovascular events.
 </span></p><h2><span class="labels">Guidelines</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Current guidelines recommend a heart rate of <110 beats per minute in asymptomatic patients with permanent atrial fibrillation without the need for strict rate control unless the patient has symptoms.
 </span></p><h2><span class="labels">Design</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Multicenter, randomized, open-label, noninferiority trial.
 </span></p><h2><span class="labels">Population</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">N=614 patients with permanent atrial fibrillation.
 </span></p><p><span class="main">Inclusion Criteria
Permanent atrial fibrillation up to 12 months, age â‰¤80 years, mean resting heart rate >80 beats per minute, and use of oral anticoagulation therapy.
 </span></p><p><span class="main">Exclusion Criteria
Disclosed previously by the study.
 </span></p><p><span class="main">Baseline Characteristics
Well matched, with a higher prevalence of coronary artery disease and statin use in the lenient-control group.
 </span></p><h2><span class="labels">Interventions</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Randomly assigned to either lenient rate-control strategy (resting heart rate <110 beats per minute) or strict rate-control strategy (resting heart rate <80 beats per minute and heart rate during moderate exercise <110 beats per minute).
 </span></p><h2><span class="labels">Outcomes</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Primary Outcome
Composite of death from cardiovascular causes, hospitalization for heart failure, and stroke, systemic embolism, bleeding, and life-threatening arrhythmic events: 12.9% in lenient-control group vs. 14.9% in strict-control group at 3 years (P<0.001 for noninferiority).
 </span></p><h2><span class="labels">Outcomes</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Similar frequencies of the components of the primary outcome between groups.
 </span></p><h2><span class="labels">Criticisms</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Study population may be considered low-risk, physically active patients, potentially limiting generalizability.
 </span></p><h2><span class="labels">Funding</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Supported by the Netherlands Heart Foundation, AstraZeneca, Biotronik, Boehringer Ingelheim, Boston Scientific, Medtronic, Roche, and Sanofi Aventis France.
 </span></p><h2><span class="labels">Further Reading</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">The original publication and supplementary material can be accessed through The New England Journal of Medicine website. </span></p>    	
        <div class="footer">Footer</div>
        </body>
        </html>